Sustained Drug Delivery Systems for Treatment of Age Related Macular Degeneration: A Review
Journal of Ophthalmic and Optometric Sciences,
Vol. 7 No. 3 (2023),
17 July 2024
,
Page 26-32
Abstract
The number of people with age-related visual problems, such as macular degeneration, has increased in recent decades due to population aging. Currently, many pharmacologic therapies exist for age-related macular degeneration (AMD), however none have satisfactory results. This underlines the need for novel drug delivery systems to improve pharmacological drug concentrations at specific locations, thereby boosting treatment effects. This study includes the current findings on sustained drug delivery systems focused at improving treatment results for patients with AMD.
- Age-Related Macular Degeneration
- Drug Delivery System
- Review
How to Cite
References
- Ayoub T, Patel N. Age-related macular degeneration. J R Soc Med. 2009;102(2):56-61.
- Gehrs KM, Anderson DH, Johnson LV, Hageman GS. Age-related macular degeneration--emerging pathogenetic and therapeutic concepts. Ann Med. 2006;38(7):450-71.
- Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, et al. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004;82(11):844-51.
- Jiménez-Gómez Y, Alba-Molina D, Blanco-Blanco M, Pérez-Fajardo L, Reyes-Ortega F, Ortega-Llamas L, et al. Novel Treatments for Age-Related Macular Degeneration: A Review of Clinical Advances in Sustained Drug Delivery Systems. Pharmaceutics. 2022;14(7):1473.
- Gheorghe A, Mahdi L, Musat O. Age-Related Macular Degeneration. Rom J Ophthalmol. 2015;59(2):74-7.
- Prokofyeva E, Zrenner E. Epidemiology of major eye diseases leading to blindness in Europe: a literature review. Ophthalmic Res. 2012;47(4):171-88.
- Rowe-Rendleman CL, Durazo SA, Kompella UB, Rittenhouse KD, Di Polo A, Weiner AL, et al. Drug and gene delivery to the back of the eye: from bench to bedside. Invest Ophthalmol Vis Sci. 2014;55(4):2714-30.
- Varela-Fernández R, Díaz-Tomé V, Luaces-Rodríguez A, Conde-Penedo A, García-Otero X, Luzardo-Álvarez A, et al. Drug Delivery to the Posterior Segment of the Eye: Biopharmaceutic and Pharmacokinetic Considerations. Pharmaceutics. 2020;12(3):269.
- Galindo-Camacho RM, Blanco-Llamero C, da Ana R, Fuertes MA, Señoráns FJ, Silva AM, et al. Therapeutic Approaches for Age-Related Macular Degeneration. Int J Mol Sci. 2022;23(19):11769.
- Shastri DH, Silva AC, Almeida H. Ocular Delivery of Therapeutic Proteins: A Review. Pharmaceutics. 2023;15(1):205.
- Bowes Rickman C, Farsiu S, Toth CA, Klingeborn M. Dry age-related macular degeneration: mechanisms, therapeutic targets, and imaging. Invest Ophthalmol Vis Sci. 2013;54(14):ORSF68-80.
- Schwartz R, Warwick A, Olvera-Barrios A, Pikoula M, Lee AY, Denaxas S, et al. Evolving Treatment Patterns and Outcomes of Neovascular Age-Related Macular Degeneration Over a Decade. Ophthalmol Retina. 2021;5(8):e11-22.
- Flaxel CJ, Adelman RA, Bailey ST, Fawzi A, Lim JI, Vemulakonda GA, Ying GS. Age-Related Macular Degeneration Preferred Practice Pattern®. Ophthalmology. 2020;127(1):P1-65.
- Cox JT, Eliott D, Sobrin L. Inflammatory Complications of Intravitreal Anti-VEGF Injections. J Clin Med. 2021;10(5):981.
- Ghasemi M, Alizadeh E, Saei Arezoumand K, Fallahi Motlagh B, Zarghami N. Ciliary neurotrophic factor (CNTF) delivery to retina: an overview of current research advancements. Artif Cells Nanomed Biotechnol. 2018;46(8):1694-707.
- Kauper K, McGovern C, Sherman S, Heatherton P, Rapoza R, Stabila P, et al. Two-year intraocular delivery of ciliary neurotrophic factor by encapsulated cell technology implants in patients with chronic retinal degenerative diseases. Invest Ophthalmol Vis Sci. 2012;53(12):7484-91.
- Zhang K, Hopkins JJ, Heier JS, Birch DG, Halperin LS, Albini TA, et al. Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. Proc Natl Acad Sci U S A. 2011;108(15):6241-5.
- Kuppermann BD, Patel SS, Boyer DS, Augustin AJ, Freeman WR, Kerr KJ, et al. Phase 2 Study of the Safety and Efficacy of Brimonidine Drug Delivery System (BRIMO DDS) Generation 1 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration. Retina. 2021;41(1):144-55.
- Freeman WR, Bandello F, Souied E, Guymer RH, Garg SJ, Chen FK, et al. Randomized Phase IIb Study of Brimonidine Drug Delivery System Generation 2 for Geographic Atrophy in Age-Related Macular Degeneration. Ophthalmol Retina. 2023;7(7):573-85.
- Campochiaro PA, Marcus DM, Awh CC, Regillo C, Adamis AP, Bantseev V, et al. The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration: Results from the Randomized Phase 2 Ladder Clinical Trial. Ophthalmology. 2019;126(8):1141-54.
- Eichenbaum DA, Ahmed A, Hiya F. Ranibizumab port delivery system: a clinical perspective. BMJ Open Ophthalmology. 2022;7:e001104.
- Ranade SV, Wieland MR, Tam T, Rea JC, Horvath J, Hieb AR, et al. The Port Delivery System with ranibizumab: a new paradigm for long-acting retinal drug delivery. Drug Deliv. 2022;29(1):1326-34.
- Chandrasekaran PR, Madanagopalan VG. Ranibizumab port delivery system in neovascular age-related macular degeneration. Ther Adv Ophthalmol. 2022;14:25158414211072623.
- Regillo C, Berger B, Brooks L, Clark WL, Mittra R, Wykoff CC, et al. Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year Results. Ophthalmology. 2023;130(7):735-47.
- Chang MA, Kapre A, Kaufman D, Kardatzke DR, Rabena M, Patel S, et al. Patient Preference and Treatment Satisfaction With a Port Delivery System for Ranibizumab vs Intravitreal Injections in Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial. JAMA Ophthalmol. 2022;140(8):771-8.
- Augustin A. Anecortave acetate in the treatment of age-related macular degeneration. Clin Interv Aging. 2006;1(3):237-46.
- Augustin AJ, D'Amico DJ, Mieler WF, Schneebaum C, Beasley C. Safety of posterior juxtascleral depot administration of the angiostatic cortisene anecortave acetate for treatment of subfoveal choroidal neovascularization in patients with age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2005;243(1):9-12.
- Regillo CD, D'Amico DJ, Mieler WF, Schneebaum C, Beasley CH, Sullins GT. Clinical safety profile of posterior juxtascleral depot administration of anecortave acetate 15 mg suspension as primary therapy or adjunctive therapy with photodynamic therapy for treatment of wet age-related macular degeneration. Surv Ophthalmol. 2007;52 Suppl 1:S70-8.
- Lim JI, Niec M, Wong V. One year results of a phase 1 study of the safety and tolerability of combination therapy using sustained release intravitreal triamcinolone acetonide and ranibizumab for subfoveal neovascular AMD. Br J Ophthalmol. 2015;99(5):618-23.
- Kuppermann BD, Goldstein M, Maturi RK, Pollack A, Singer M, Tufail A, et al. Dexamethasone Intravitreal Implant as Adjunctive Therapy to Ranibizumab in Neovascular Age-Related Macular Degeneration: A Multicenter Randomized Controlled Trial. Ophthalmologica. 2015;234(1):40-54.
- Geltzer A, Turalba A, Vedula SS. Surgical implantation of steroids with antiangiogenic characteristics for treating neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2013;1(1):CD005022.
- Gopal L, Sharma T. Use of intravitreal injection of triamcinolone acetonide in the treatment of age-related macular degeneration. Indian J Ophthalmol. 2007;55(6):431-5.
- Jemni-Damer N, Guedan-Duran A, Fuentes-Andion M, Serrano-Bengoechea N, Alfageme-Lopez N, Armada-Maresca F, et al. Biotechnology and Biomaterial-Based Therapeutic Strategies for Age-Related Macular Degeneration. Part I: Biomaterials-Based Drug Delivery Devices. Front Bioeng Biotechnol. 2020;8:549089.
- Abstract Viewed: 17 times
- pdf Downloaded: 15 times
